Patents by Inventor Thierry Guillaudeux

Thierry Guillaudeux has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTI-VISTA ANTIBODIES AND USES THEREOF
    Publication number: 20240132593
    Abstract: The present disclosure provides antibodies to V-domain Ig-containing Suppressor of T cell Activation (VISTA) and compositions comprising such antibodies. Also provided are methods of using antibodies that specifically binds to VISTA to treat diseases, e.g., to treat cancer.
    Type: Application
    Filed: February 18, 2022
    Publication date: April 25, 2024
    Inventors: Shawn P. Iadonato, Thierry Guillaudeux, Eric J. Tarcha, David Scott Johnson, Adam Shultz Adler, Rena Aviva Mizrahi, Yoong Wearn Lim, Michael Asensio
  • Selective c-FLIP Inhibitors as Anticancer Agents
    Publication number: 20190282563
    Abstract: The present invention provides nine selective c-FLIP inhibitors that are useful in the treatment of cancer, alone or in combination with other chemotherapeutic agents, in particular with TRAIL-based chemotherapeutic agents. The present invention also relates to pharmaceutical compositions and kits comprising at least one of the nine selective c-FLIP inhibitors and their use in methods for the treatment of cancer, in particular to overcome chemoresistance or to improve sensitivity of tumors to TRAIL-based therapy.
    Type: Application
    Filed: November 17, 2017
    Publication date: September 19, 2019
    Applicants: Centre National de la Recherche Scientifique, Universite de Rennes 1, Universite d'Orleans
    Inventors: Katherine YAACOUB, Thierry GUILLAUDEUX, Richard DANIELLOU, Pierre LAFITE, Samia ACI-SECHE, Pascal BONNET
  • Detection of mutations in a gene associated with resistance to viral infection, OAS1
    Patent number: 9090947
    Abstract: A method for detecting a mutation related to the gene encoding OAS1. This and other disclosed mutations correlate with resistance of humans to viral infection including hepatitis C. Also provided is a therapeutic agent consisting of a protein or polypeptide encoded by the mutated gene, or a polynucleotide encoding the protein or polypeptide. Inhibitors of human OAS1, including antisense oligonucleotides, methods, and compositions specific for human OAS1, are also provided.
    Type: Grant
    Filed: May 28, 2013
    Date of Patent: July 28, 2015
    Assignee: Kineta Two, LLC
    Inventors: Shawn P. Iadonato, Charles L. Magness, Gary Rosenberg, Christina A. Scherer, Thierry Guillaudeux
  • Detection of Mutations in a Gene Associated with Resistance to Viral Infection, OAS1
    Publication number: 20140037717
    Abstract: A method for detecting a mutation related to the gene encoding OAS1. This and other disclosed mutations correlate with resistance of humans to viral infection including hepatitis C. Also provided is a therapeutic agent consisting of a protein or polypeptide encoded by the mutated gene, or a polynucleotide encoding the protein or polypeptide. Inhibitors of human OAS1, including antisense oligonucleotides, methods, and compositions specific for human OAS1, are also provided.
    Type: Application
    Filed: September 5, 2013
    Publication date: February 6, 2014
    Applicant: Kineta Two, LLC
    Inventors: Shawn P Iadonato, Charles L Magness, Gary Rosenberg, Christina A Scherer, Thierry Guillaudeux
  • Detection of Mutations in a Gene Associated with Resistance to Viral Infection, OAS1
    Publication number: 20140010800
    Abstract: A method for detecting a mutation related to the gene encoding OAS1. This and other disclosed mutations correlate with resistance of humans to viral infection including hepatitis C. Also provided is a therapeutic agent consisting of a protein or polypeptide encoded by the mutated gene, or a polynucleotide encoding the protein or polypeptide. Inhibitors of human OAS1, including antisense oligonucleotides, methods, and compositions specific for human OAS1, are also provided.
    Type: Application
    Filed: May 28, 2013
    Publication date: January 9, 2014
    Inventors: Shawn P. Iadonato, Charles L. Magness, Gary Rosenberg, Christina A. Scherer, Thierry Guillaudeux
  • Detection of mutations in a gene associated with resistance to viral infection, OAS1
    Patent number: 8551772
    Abstract: A method for detecting a mutation related to the gene encoding OAS1. This and other disclosed mutations correlate with resistance of humans to viral infection including hepatitis C. Also provided is a therapeutic agent consisting of a protein or polypeptide encoded by the mutated gene, or a polynucleotide encoding the protein or polypeptide. Inhibitors of human OAS1, including antisense oligonucleotides, methods, and compositions specific for human OAS1, are also provided.
    Type: Grant
    Filed: November 22, 2011
    Date of Patent: October 8, 2013
    Assignee: Kineta Two, LLC
    Inventors: Shawn P Iadonato, Charles L Magness, Gary Rosenberg, Christina A Scherer, Thierry Guillaudeux
  • DETECTION OF MUTATIONS IN A GENE ASSOCIATED WITH RESISTANCE TO VIRAL INFECTION, OAS1
    Publication number: 20120321608
    Abstract: A method for detecting a mutation related to the gene encoding OAS1. This and other disclosed mutations correlate with resistance of humans to viral infection including hepatitis C. Also provided is a therapeutic agent consisting of a protein or polypeptide encoded by the mutated gene, or a polynucleotide encoding the protein or polypeptide. Inhibitors of human OAS1, including antisense oligonucleotides, methods, and compositions specific for human OAS1, are also provided.
    Type: Application
    Filed: May 10, 2012
    Publication date: December 20, 2012
    Applicant: Kineta Two, LLC
    Inventors: SHAWN P. IADONATO, Charles L. Magness, Gary Rosenberg, Christina A. Scherer, Thierry Guillaudeux
  • DETECTION OF MUTATIONS IN A GENE ASSOCIATED WTIH RESISTANCE TO VIRAL INFECTION, OAS1
    Publication number: 20120253027
    Abstract: A method for detecting a mutation related to the gene encoding OAS1. This and other disclosed mutations correlate with resistance of humans to viral infection including hepatitis C. Also provided is a therapeutic agent consisting of a protein or polypeptide encoded by the mutated gene, or a polynucleotide encoding the protein or polypeptide. Inhibitors of human OAS1, including antisense oligonucleotides, methods, and compositions specific for human OAS1, are also provided.
    Type: Application
    Filed: November 22, 2011
    Publication date: October 4, 2012
    Applicant: KINETA TWO, LLP
    Inventors: Shawn P. Iadonato, CHARLES L. MAGNESS, GARY ROSENBERG, CHRISTINA A. SCHERER, THIERRY GUILLAUDEUX
  • Detection of mutations in a gene associated with resistance to viral infection, OAS1
    Patent number: 8192973
    Abstract: A method for detecting a mutation related to the gene encoding OAS1. This and other disclosed mutations correlate with resistance of humans to viral infection including hepatitis C. Also provided is a therapeutic agent consisting of a protein or polypeptide encoded by the mutated gene, or a polynucleotide encoding the protein or polypeptide. Inhibitors of human OAS1, including antisense oligonucleotides, methods, and compositions specific for human OAS1, are also provided.
    Type: Grant
    Filed: November 2, 2006
    Date of Patent: June 5, 2012
    Assignee: Kineta Two, LLC
    Inventors: Shawn P Iadonato, Charles L Magness, Gary Rosenberg, Christina A Scherer, Thierry Guillaudeux
  • Detection of mutations in a gene associated with resistance to viral infection, OAS1
    Patent number: 8088907
    Abstract: A method for detecting a mutation related to the gene encoding OAS1. This and other disclosed mutations correlate with resistance of humans to viral infection including hepatitis C. Also provided is a therapeutic agent consisting of a protein or polypeptide encoded by the mutated gene, or a polynucleotide encoding the protein or polypeptide. Inhibitors of human OAS1, including antisense oligonucleotides, methods, and compositions specific for human OAS1, are also provided.
    Type: Grant
    Filed: April 2, 2008
    Date of Patent: January 3, 2012
    Assignee: Kineta Two, LLC
    Inventors: Shawn P. Iadonato, Charles L. Magness, Gary Rosenberg, Christina A. Scherer, Thierry Guillaudeux
  • Detection of Mutations in a Gene Associated with Resistance to Viral Infection, OAS1
    Publication number: 20110237501
    Abstract: A method for detecting a mutation related to the gene encoding OAS1. This and other disclosed mutations correlate with resistance of humans to viral infection including hepatitis C. Also provided is a therapeutic agent consisting of a protein or polypeptide encoded by the mutated gene, or a polynucleotide encoding the protein or polypeptide. Inhibitors of human OAS1, including antisense oligonucleotides, methods, and compositions specific for human OAS1, are also provided.
    Type: Application
    Filed: April 7, 2011
    Publication date: September 29, 2011
    Inventors: Shawn P. Iadonato, Charles L. Magness, Gary Rosenberg, Christina A. Scherer, Thierry Guillaudeux
  • Detection of mutations in a gene associated with resistance to viral infection, OAS1
    Publication number: 20070154467
    Abstract: A method for detecting a mutation related to the gene encoding OAS1. This and other disclosed mutations correlate with resistance of humans to viral infection including hepatitis C. Also provided is a therapeutic agent consisting of a protein or polypeptide encoded by the mutated gene, or a polynucleotide encoding the protein or polypeptide. Inhibitors of human OAS1, including antisense oligonucleotides, methods, and compositions specific for human OAS1, are also provided.
    Type: Application
    Filed: November 2, 2006
    Publication date: July 5, 2007
    Applicant: Illumigen Biosciences, Inc.
    Inventors: Shawn Iadonato, Charles Magness, Gary Rosenberg, Christina Scherer, Thierry Guillaudeux